MedTrace Logo

Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan

NCT00603512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2013-01-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety, over 3 months, of 4 dose regimens of CP-690,550, combined with methotrexate, for the treatment with active rheumatoid arthritis.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Placebo

0 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

10 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

1 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

3 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

5 mg BID, 3 blinded tablets administered BID for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603512 on ClinicalTrials.gov